| For: | Chen JH, Dai XC, Quan ZJ, Liu XY. Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation. World J Diabetes 2025; 16(6): 103685 [PMID: 40548264 DOI: 10.4239/wjd.v16.i6.103685] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i6/103685.htm |
| Number | Citing Articles |
| 1 |
Huixiang Zhang, Xue Yang, Yingwanqi Wang, Wei Xiao, Yu Zhao, Fengkai Wu, Hongyu Liu, Shan Ren, Yang Liu, Yan Lin, Jun Wang, Guangwei Li. Paeoniflorin suppresses cardiomyocyte pyroptosis and ameliorates diabetic cardiomyopathy by AMPK/Nrf2/NLRP3 pathway. International Immunopharmacology 2026; 171 doi: 10.1016/j.intimp.2025.116122
|
| 2 |
Mengqi Zhu, Xi Yang, Jingmin Xie, Xiaojing Shi, Jiajing Li, Yuhua Shi, Lijiang Zhang, Xinyao Tian, Yang Li, Jihong Yao, Ruimin Sun. Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis. European Journal of Pharmacology 2026; 1030 doi: 10.1016/j.ejphar.2026.179110
|
| 3 |
Chengyi Ming, Ni Zhu, You Yu, Hong Zhou, Meichun Hu. Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review). International Journal of Molecular Medicine 2026; 58(1) doi: 10.3892/ijmm.2026.5854
|